Specific immunotherapy of experimental myasthenia gravis by a novel mechanism

Annals of Neurology

Volumn 67, Issue 4, 2010, Pages 441-451

  Luo, Jie ^a   Kuryatov, Alexander ^a   Lindstrom, Jon M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BUNGAROTOXIN; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G; IODINE 125; OVALBUMIN; RECEPTOR SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; EXPERIMENTAL MODEL; IMMUNIZATION; IMMUNOTHERAPY; ISOTOPE LABELING; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; OVALBUMIN; PEPTIDE FRAGMENTS; PROTEIN SUBUNITS; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; TIME FACTORS;

EID: 77951734506     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21901     Document Type: Article

References (48)

1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843-2854.
2. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 2000;23:453-477.
3. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357:2122-2128.
4. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973;180:871-872.
5. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89:73-120.
6. Tzartos SJ, Barkas T, Cung MT, et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998;163:89-120. (Pubitemid 28327864)
7. Luo J, Taylor P, Losen M, et al. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci (in press).
8. Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci U S A 1982;79:188-192.
9. Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 1995; 15:323-331.
10. Froehner SC. Identification of exposed and buried determinants of the membrane-bound acetylcholine receptor from Torpedo californica. Biochemistry 1981;20:4905-4915.
11. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505. (Pubitemid 38451340)
12. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004;24:17-20.
13. Bartfeld D, Fuchs S. Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor. Proc Natl Acad Sci U S A 1978;75:4006-4010. (Pubitemid 8399861)
14. Krolick KA, Yeh TM, Edlund SA. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis. Cell Immunol 1996;172:10-20.
15. Liblau R, Tisch R, Bercovici N, McDevitt HO. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol Today 1997;18:599-604. (Pubitemid 28010972)
16. Weiner HL. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 1997;48:341-351. (Pubitemid 27101836)
17. Xiao BG, Link H. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 1997;85:119-128. (Pubitemid 27512953)
18. Barchan D, Souroujon MC, Im SH, et al. Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor α-subunit. Proc Natl Acad Sci U S A 1999;96:8086-8091. (Pubitemid 29328412)
19. Drachman DB, Okumura S, Adams RN, McIntosh KR. Oral tolerance in myasthenia gravis. Ann N Y Acad Sci 1996;778:258-272.
20. Karachunski PI, Ostlie NS, Okita DK, Conti-Fine BM. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J Clin Invest 1997;100:3027-3035.
21. Lindstrom J, Peng X, Kuryatov A, et al. Molecular and antigenic structure of nicotinic acetylcholine receptors. Ann N Y Acad Sci 1998;841:71-86. (Pubitemid 28362830)
22. Ma CG, Zhang GX, Xiao BG, et al. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol 1995;58:51-60.
23. Shi FD, Li H, Wang H, et al. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol 1999;162:5757-5763. (Pubitemid 29314926)
24. Wang ZY, Huang J, Olsson T, et al. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. J Neurol Sci 1995;128:167-174.
25. Maiti PK, Feferman T, Im SH, et al. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol 2004;152:112-120. (Pubitemid 38829708)
26. Im SH, Barchan D, Souroujon MC, Fuchs S. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J Immunol 2000;165:3599-3605. (Pubitemid 32057262)
27. Lindstrom J, Luo J, Kuryatov A. Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains. Ann N Y Acad Sci 2008;1132:29-41. (Pubitemid 351841350)
28. Lindstrom JM, Lennon VA, Seybold ME, Whittingham S. Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci 1976;274:254-274.
29. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci 1976;274:283-299.
30. Protti MP, Manfredi AA, Horton RM, et al. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today 1993;14:363-368.
31. Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009;72:1548-1554.
32. Yi HJ, Chae CS, So JS, et al. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor. Mol Immunol 2008;46:192-201.
33. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;16:183-200. (Pubitemid 34852318)
34. Im SH, Barchan D, Fuchs S, Souroujon MC. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest 1999;104: 1723-1730. (Pubitemid 30053189)
35. Shi FD, Bai XF, Li HL, et al. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals. Clin Exp Immunol 1998;111: 506-512. (Pubitemid 28160892)
36. Lennon VA, Lambert EH, Leiby KR, et al. Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 1991;146:2245-2248.
37. Lindstrom J, Einarson B, Merlie J. Immunization of rats with polypeptide chains from torpedo acetylcholine receptor causes an autoimmune response to receptors in rat muscle. Proc Natl Acad Sci U S A 1978;75:769-773. (Pubitemid 8319455)
38. Tzartos SJ, Remoundos M. Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients. Clin Exp Immunol 1999;116:146-152. (Pubitemid 29170018)
39. Mamalaki A, Trakas N, Tzartos SJ. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Eur J Immunol 1993;23:1839-1845. (Pubitemid 23236775)
40. Balasa B, Deng C, Lee J, et al. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 1998;161:2856-2862. (Pubitemid 28425707)
41. Balasa B, Sarvetnick N. Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis. Immunol Today 2000;21:19-23. (Pubitemid 30410694)
42. Saoudi A, Bernard I, Hoedemaekers A, et al. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1-or Th2-type immune response in rats. J Immunol 1999; 162:7189-7197. (Pubitemid 29277690)
43. Link J, Soderstrom M, Ljungdahl A, et al. Organ-specific autoantigens induce interferon-γ and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 1994;44:728-734. (Pubitemid 24130007)
44. Yi Q, Lefvert AK. Idiotype-and anti-idiotype-reactive T lymphocytes in myasthenia gravis. Evidence for the involvement of different subpopulations of T helper lymphocytes. J Immunol 1994; 153:3353-3359. (Pubitemid 24292562)
45. De Baets M, Stassen M, Losen M, et al. Immunoregulation in experimental autoimmune myasthenia gravis-about T cells, antibodies, and endplates. Ann N Y Acad Sci 2003;998:308-317. (Pubitemid 37194172)
46. Medgyesi GA, Fust G, Gergely J, Bazin H. Classes and subclasses of rat immunoglobulins: interaction with the complement system and with staphylococcal protein A. Immunochemistry 1978;15:125-129. (Pubitemid 8268028)
47. Gomez CM, Richman DP. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol 1985;135:234-241.
48. Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987;15:185-194. (Pubitemid 17075151)